CA3138145A1 - Anti-abeta vaccine therapy - Google Patents

Anti-abeta vaccine therapy Download PDF

Info

Publication number
CA3138145A1
CA3138145A1 CA3138145A CA3138145A CA3138145A1 CA 3138145 A1 CA3138145 A1 CA 3138145A1 CA 3138145 A CA3138145 A CA 3138145A CA 3138145 A CA3138145 A CA 3138145A CA 3138145 A1 CA3138145 A1 CA 3138145A1
Authority
CA
Canada
Prior art keywords
vaccine composition
liposomal vaccine
disease
administered
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3138145A
Other languages
English (en)
French (fr)
Inventor
Andrea Pfeifer
Andreas MUHS (deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of CA3138145A1 publication Critical patent/CA3138145A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3138145A 2019-05-21 2020-05-20 Anti-abeta vaccine therapy Pending CA3138145A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP19175810.1 2019-05-21
EP19175810 2019-05-21
EP19185593.1 2019-07-10
EP19185593 2019-07-10
EP20171549 2020-04-27
EP20171549.7 2020-04-27
EP20172205 2020-04-29
EP20172205.5 2020-04-29
PCT/EP2020/064172 WO2020234405A1 (en) 2019-05-21 2020-05-20 Anti-abeta vaccine therapy

Publications (1)

Publication Number Publication Date
CA3138145A1 true CA3138145A1 (en) 2020-11-26

Family

ID=70740677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3138145A Pending CA3138145A1 (en) 2019-05-21 2020-05-20 Anti-abeta vaccine therapy

Country Status (15)

Country Link
US (1) US20220226447A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972633A1 (cg-RX-API-DMAC7.html)
JP (1) JP7701734B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220010552A (cg-RX-API-DMAC7.html)
CN (1) CN113853214A (cg-RX-API-DMAC7.html)
AU (1) AU2020277682A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023209A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138145A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003051A1 (cg-RX-API-DMAC7.html)
IL (1) IL288252B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014102A (cg-RX-API-DMAC7.html)
MY (1) MY210394A (cg-RX-API-DMAC7.html)
SG (1) SG11202112329RA (cg-RX-API-DMAC7.html)
TW (1) TW202110425A (cg-RX-API-DMAC7.html)
WO (1) WO2020234405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI916375B (zh) * 2020-06-25 2026-03-01 英商梅迪繆思有限公司 軸突損傷之預防
WO2024156912A1 (en) * 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy
WO2025109524A1 (en) * 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
MA52180A (fr) * 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta

Also Published As

Publication number Publication date
IL288252A (en) 2022-01-01
JP2022533422A (ja) 2022-07-22
MY210394A (en) 2025-09-18
KR20220010552A (ko) 2022-01-25
CN113853214A (zh) 2021-12-28
SG11202112329RA (en) 2021-12-30
JP7701734B2 (ja) 2025-07-02
IL288252B1 (en) 2026-06-01
TW202110425A (zh) 2021-03-16
US20220226447A1 (en) 2022-07-21
WO2020234405A1 (en) 2020-11-26
BR112021023209A2 (pt) 2022-01-18
MX2021014102A (es) 2022-02-11
EP3972633A1 (en) 2022-03-30
CL2021003051A1 (es) 2022-07-22
AU2020277682A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
Monsonego et al. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease
JP5889529B2 (ja) アミロイド原性疾患の処置
US12324855B2 (en) Method of safe administration of phosphorylated Tau peptide vaccine
US20220226447A1 (en) Anti-abeta vaccine therapy
US20080248055A1 (en) Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
EA032494B1 (ru) N-КОНЦЕВОЙ Аβ1-15 АНТИГЕННЫЙ ПЕПТИД ДЛЯ ЛЕЧЕНИЯ ИНДИВИДУУМА С СИНДРОМОМ ДАУНА
US11567078B2 (en) Blood cell biomarker for late onset Alzheimer's disease
US9707284B2 (en) Formulations of peptides and chloroquines for the treatment of pathogenic immune responses in immune mediated diseases
WO2015165980A2 (en) Treatment and prevention of alzheimer's disease (ad)
EA049756B1 (ru) Терапия с помощью вакцины против бета-амилоида
HK40058406A (en) Anti-abeta vaccine therapy
US20080226668A1 (en) Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
KR102388363B1 (ko) 알츠하이머병(ad)의 치료 및 예방
US20050250691A1 (en) Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
EP4654990A1 (en) Anti-abeta vaccine therapy
US20250049900A1 (en) Method of safe administration of tau phosphopeptide conjugate
TW201712027A (zh) 多肽組合物
WO2023004044A2 (en) Compositions and methods for treating neurodegenerative diseases by inhibiting fsh
SCHNABEL et al. 274 End Results

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240516

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250415

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250415

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260413

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260414

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260423

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260423